Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population

Digestive Diseases and Sciences

Volumn 56, Issue 5, 2011, Pages 1489-1495

  Chiorean, Michael V ^a   Pokhrel, Bhupesh ^a   Adabala, Jaya ^a   Helper, Debra J ^a   Johnson, Cynthia S ^a   Juliar, Beth ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bowel disease; Lymphoproliferative disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENTERITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZED INCIDENCE RATIO;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INDIANA; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79955601728     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1430-z     Document Type: Article

References (35)

1. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005;21:44-50. (Pubitemid 40189223)
2. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869. (Pubitemid 9242048)
3. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266. (Pubitemid 14218578)
4. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
5. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. (Pubitemid 41820634)
6. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
7. Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975;64:365-370.
8. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. (Pubitemid 34851835)
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250. (Pubitemid 47080388)
12. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. (Pubitemid 40824691)
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
14. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667. (Pubitemid 351284485)
15. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647-653.
16. Arseneau KO, Stukenborg GJ, Connors AF Jr, Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis. 2001;7:106-112. (Pubitemid 32998497)
17. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862. (Pubitemid 32173312)
18. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-1087. (Pubitemid 33022087)
19. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622. (Pubitemid 40559243)
20. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control Study. Am J Gastroenterol 2010.
21. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31. (Pubitemid 38040720)
22. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. (Pubitemid 38662135)
23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. (Pubitemid 43736578)
24. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
25. McDonald CJ, Overhage JM, Barnes M, et al. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood). 2005;24:1214-1220.
26. McDonald CJ, Overhage JM, Tierney WM, et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform. 1999;54:225-253. (Pubitemid 29276954)
27. Overhage J, McDonald CJ, Suico JG. The Regenstrief medical record system 2000:Expanding the breadth and depth of a community wide EMR. Proc AMIA Symp 2000:1173.
28. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985;56:2914-2921. (Pubitemid 16216306)
29. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non- Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
30. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308-2312.
31. Feinstein AR, Walter SD, Horwitz RI. An analysis of Berkson's bias in case-control studies. J Chronic Dis. 1986;39:495-504. (Pubitemid 16070694)
32. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. (Pubitemid 41025906)
33. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625.
34. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030.
35. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653. (Pubitemid 351783447)